Payment overview · 2025
General Payments
$245.48
12 reported records · 9 companies
Healthcare provider profile · identity verified
Jared Shelby Barber, MD
Allopathic & Osteopathic Physicians|Family Medicine · BLOUNTSTOWN, FL · NPI 1104486588
Verified facts
What the public records show
CMS Open Payments records show Jared Shelby Barber, MD received $245.48 in general payments during 2025 across 12 reported records.
AstraZeneca Pharmaceuticals LP accounted for 22.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $55.64 | 22.7% | 3 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $35.92 | 14.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.67 | 13.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $27.56 | 11.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $27.02 | 11.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $18.14 | 7.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.44 | 6.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.90 | 6.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.19 | 6.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $245.48 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $55.64 | 3 | 2025 |
Source payment records
|
|||||
| Ambulatory Monitoring & Diagnostics Undivided Normalized: ambulatory monitoring diagnostics undivided |
Device | Philips North America LLC | $35.92 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $33.67 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $27.56 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $27.02 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $18.14 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.44 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 90 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 49 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
49 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
90 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
21 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 363 | 65 |
| Alprazolam | Alprazolam | 273 | 41 |
| Atorvastatin Calcium | Atorvastatin Calcium | 258 | 62 |
| Omeprazole | Omeprazole | 247 | 59 |
| Gabapentin | Gabapentin | 228 | 38 |
| Amlodipine Besylate | Amlodipine Besylate | 225 | 47 |
| Losartan Potassium | Losartan Potassium | 218 | 42 |
| Montelukast Sodium | Montelukast Sodium | 185 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 176 | 36 |
| Lisinopril | Lisinopril | 156 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 156 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 143 | 33 |
| Eliquis | Apixaban | 141 | 22 |
| Clonazepam | Clonazepam | 134 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 127 | 25 |
| Potassium Chloride | Potassium Chloride | 124 | 22 |
| Tramadol Hcl | Tramadol Hcl | 116 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 114 | 37 |
| Sertraline Hcl | Sertraline Hcl | 113 | 23 |
| Furosemide | Furosemide | 108 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 106 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 105 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 96 | 13 |
| Carvedilol | Carvedilol | 94 | 19 |
| Metformin Hcl | Metformin Hcl | 92 | 16 |
| Mounjaro | Tirzepatide | 90 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 83 | 16 |
| Simvastatin | Simvastatin | 82 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 81 | 28 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 80 | 56 |
| Allopurinol | Allopurinol | 79 | 14 |
| Ezetimibe | Ezetimibe | 79 | 13 |
| Glipizide Er | Glipizide | 79 | 17 |
| Januvia | Sitagliptin Phosphate | 79 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 78 | 14 |
| Prednisone | Prednisone | 77 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 76 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 75 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 73 | 11 |
| Metformin Hcl Er | Metformin Hcl | 73 | 16 |
| Famotidine | Famotidine | 71 | 21 |
| Lorazepam | Lorazepam | 71 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 64 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 62 | 15 |
| Trazodone Hcl | Trazodone Hcl | 61 | 15 |
| Bupropion Xl | Bupropion Hcl | 59 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 57 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | suppressed |
| Atenolol | Atenolol | 50 | suppressed |
| Azithromycin | Azithromycin | 50 | 35 |
| Jardiance | Empagliflozin | 49 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 46 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 45 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 44 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 42 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 41 | 12 |
| Farxiga | Dapagliflozin Propanediol | 40 | suppressed |
| Synthroid | Levothyroxine Sodium | 37 | suppressed |
| Irbesartan | Irbesartan | 35 | suppressed |
| Pregabalin | Pregabalin | 35 | suppressed |
| Aripiprazole | Aripiprazole | 34 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Meloxicam | Meloxicam | 34 | suppressed |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Celecoxib | Celecoxib | 32 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 32 | suppressed |
| Levofloxacin | Levofloxacin | 32 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 32 | 13 |
| Valsartan | Valsartan | 32 | suppressed |
| Topiramate | Topiramate | 31 | suppressed |
| Fluconazole | Fluconazole | 30 | 19 |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 27 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 17 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 25 | 22 |
| Promethazine Hcl | Promethazine Hcl | 25 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Cefdinir | Cefdinir | 21 | 18 |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Ozempic | Semaglutide | 21 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Repaglinide | Repaglinide | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Embrace Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $245.48 · 12 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Ambulatory Monitoring & Diagnostics Undivided, Cologuard Collection Kit, EVENITY, LEQVIO, MOUNJARO, TRELEGY ELLIPTA, UBRELVY, Wegovy, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error